Austria Leads in Pancreatic Cancer Breakthrough with Promising New Treatment

Vienna has emerged as a global hub for pancreatic cancer research after a clinical trial of the experimental drug Daraxonrasib showed a 60% reduction in mortality among patients with advanced disease, according to results presented at the American Society of Clinical Oncology (ASCO) conference in Chicago on June 1, 2024. The findings, led by Dr. Gerald Prager of MedUni Wien, mark a significant step forward in treating one of the deadliest cancers.

What Is Daraxonrasib and How Does It Work?

Developed by California-based biotech firm Revolution Medicines, Daraxonrasib targets a defective RAS protein found in 90% of pancreatic cancer tumors, according to a press release from the company. “In normal cells, RAS acts as a switch that turns cell growth on and off, but in cancer cells, it’s stuck in the ‘on’ position,” Prager explained. “Daraxonrasib effectively turns this switch off, slowing tumor progression.”

The drug belongs to a class of RAS-ON inhibitors, a novel approach that has shown promise in preclinical studies. A 2023 review in *Nature Reviews Cancer* highlighted RAS inhibitors as a “critical frontier” in oncology, though most previous attempts had failed due to the protein’s complex structure.

Key Trial Results and Patient Outcomes

The phase III trial involved 501 patients with advanced pancreatic cancer, with half receiving Daraxonrasib and the other half standard chemotherapy. Results showed:

• 60% lower risk of death compared to chemotherapy
• 13.2-month median survival versus 6.6 months for chemotherapy
• 7.3-month progression-free survival with Daraxonrasib

Patients also experienced fewer severe side effects, with only 1.2% discontinuing treatment due to adverse reactions, compared to 11.2% in the chemotherapy group, according to the study published in *The New England Journal of Medicine*.

Why This Matters for Pancreatic Cancer Patients

Pancreatic cancer remains one of the most lethal cancers, with a five-year survival rate of just 12% in Austria and 9% globally, per the World Health Organization (WHO). The new treatment offers hope for patients with late-stage disease, though it is not a cure. “We’re not talking about a miracle drug, but a meaningful improvement in quality and duration of life,” said Dr. Maria Hinterberger, a cancer specialist at the Austrian Society of Oncology.

Expanding Research to Other Cancers

Prager’s team is now testing Daraxonrasib in patients with early-stage pancreatic cancer and colorectal cancer, where RAS mutations are also common. A separate trial at the Medical University of Vienna will evaluate the drug’s efficacy when combined with chemotherapy for colorectal cancer, with results expected in 2025.

“If these trials succeed, we could see a paradigm shift in how we treat RAS-driven cancers,” said Dr. Lena Müller, a molecular biologist at the European Cancer Research Institute.

Potential Side Effects and Patient Experiences

While generally well-tolerated, Daraxonrasib has caused notable side effects, including skin rashes, mucosal inflammation, and gastrointestinal issues. One patient, Ben Sasse, described “uncontrollable bleeding” and “skin that wouldn’t heal” after starting the medication. However, the study authors noted these effects were less severe than those associated with traditional chemotherapy.

Future Prospects and Challenges

Regulatory approval for Daraxonrasib is pending, with the European Medicines Agency (EMA) expected to review the data in late 2024. If approved, the drug could become a standard treatment within two years. However, experts caution that access may be limited initially due to high costs and the need for specialized administration.

“This is a major breakthrough, but we must ensure equitable access,” said Dr. Hinterberger. “The next step is working with policymakers to make this treatment available to all patients who need it.”